{"protocolSection": {"identificationModule": {"nctId": "NCT00987415", "orgStudyIdInfo": {"id": "Pro00020011"}, "secondaryIdInfos": [{"id": "5U10HL084904", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/5U10HL084904"}], "organization": {"fullName": "Duke University", "class": "OTHER"}, "briefTitle": "Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels", "officialTitle": "Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients", "acronym": "EXACT-HF"}, "statusModule": {"statusVerifiedDate": "2014-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-05"}, "primaryCompletionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-09-30", "studyFirstSubmitQcDate": "2009-09-30", "studyFirstPostDateStruct": {"date": "2009-10-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-10-14", "resultsFirstSubmitQcDate": "2014-10-14", "resultsFirstPostDateStruct": {"date": "2014-10-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-10-28", "lastUpdatePostDateStruct": {"date": "2014-11-04", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Duke University", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether allopurinol is effective in relieving symptoms of patients with heart failure and high blood uric acid levels."}, "conditionsModule": {"conditions": ["Heart Failure", "Elevated Serum Uric Acid"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 253, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "allopurinol", "type": "ACTIVE_COMPARATOR", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.", "interventionNames": ["Drug: allopurinol"]}, {"label": "sugar pill", "type": "PLACEBO_COMPARATOR", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.", "interventionNames": ["Drug: sugar pill"]}], "interventions": [{"type": "DRUG", "name": "allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.", "armGroupLabels": ["allopurinol"]}, {"type": "DRUG", "name": "sugar pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.", "armGroupLabels": ["sugar pill"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "A Composite Clinical Endpoint (CCE) That Classifies Subject's Clinical Status as Improved, Worsened, or Unchanged.", "description": "CCE composed of 3-level categorical variable with options that include worsened, unchanged or improved", "timeFrame": "24 Weeks"}], "secondaryOutcomes": [{"measure": "Change in Quality of Life (KCCQ).", "description": "Kansas City Cardiomyopathy (KCCQ) overall summary score - The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change in Submaximal Exercise Capacity (6-MWT)", "description": "6-Minute Walk Test", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change in Quality of Life (KCCQ)", "description": "Kansas City Cardiomyopathy (KCCQ) overall summary score - The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.", "timeFrame": "Baseline to 24 weeks"}, {"measure": "Change in Submaximal Exercise Capacity (6-MWT)", "description": "6-Minute Walk Test", "timeFrame": "Baseline to 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* NYHA class II-IV heart failure due to ischemic or non-ischemic cardiomyopathy.\n* Left ventricular ejection fraction \u2264 40% by echocardiography- Heart failure symptoms for 3 months despite standard treatment.\n* Serum uric acid level \u2265 9.5 mg/dl.\n* At least one of the following additional markers of increased risk: Hospitalization, ER visit or urgent clinic visit for heart failure requiring IV diuretics within the previous 12 months; Left ventricular ejection fraction \u2264 25; B-type natriuretic peptide level \\> 250 pg/ml\n\nExclusion Criteria:\n\n* Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, biopsy-proven myocarditis, severe stenotic valvular disease, or complex congenital heart disease.\n* Acute coronary syndrome, PCI or CABG within 3 months.\n* Current ventricular assist device or ventricular assist device or heart transplant likely within the next 6 months.\n* Uncontrolled hypertension (i.e., SBP \\> 170 mm Hg or DBP \\> 110 mm Hg)\n* Serum creatinine \\> 3 mg/dL or estimated GFR \\< 20 ml/min.\n* Evidence of active hepatitis with ALT and AST greater than 3x normal.\n* Any condition other than HF which could limit the ability to perform a 6-minute walk test\n* Any diseases other than HF which are likely to alter the patient's global perception of status or quality of life over a period of 6 months.\n* Receiving treatment with allopurinol currently or within 30 days, or having symptomatic hyperuricemia which requires treatment with allopurinol.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Eugene Braunwald, MD", "affiliation": "Harvard University", "role": "STUDY_CHAIR"}, {"name": "Alice Mascette, MD", "affiliation": "National Heart, Lung, and Blood Institute (NHLBI)", "role": "STUDY_DIRECTOR"}, {"name": "Adrian Hernandez, MD", "affiliation": "Duke University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Morehouse School of Medicine", "city": "Atlanta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Harvard University", "city": "Boston", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "University of Minnesota", "city": "Minneapolis", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "University Hospitals-Case Medical Center", "city": "Cleveland", "state": "Ohio", "zip": "44106", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Baylor College of Medicine", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Univ. of Utah Health Sciences Center", "city": "Salt Lake City", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "University of Vermont", "city": "Burlington", "state": "Vermont", "country": "United States", "geoPoint": {"lat": 44.47588, "lon": -73.21207}}, {"facility": "University of Montreal", "city": "Montreal PQ", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}]}, "referencesModule": {"references": [{"pmid": "25986447", "type": "DERIVED", "citation": "Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19;131(20):1763-71. doi: 10.1161/CIRCULATIONAHA.114.014536. Epub 2015 Apr 14."}, {"pmid": "21849262", "type": "DERIVED", "citation": "Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271-85. doi: 10.1016/j.amjopharm.2011.07.004. Epub 2011 Aug 17."}], "seeAlsoLinks": [{"label": "Trial Website", "url": "http://www.hfnetwork.org"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nallopurinol: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}, {"id": "FG001", "title": "Sugar Pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nsugar pill: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "128"}, {"groupId": "FG001", "numSubjects": "125"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "119"}, {"groupId": "FG001", "numSubjects": "116"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nallopurinol: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}, {"id": "BG001", "title": "Sugar Pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nsugar pill: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "125"}, {"groupId": "BG002", "value": "253"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.1", "spread": "14.2"}, {"groupId": "BG001", "value": "61.8", "spread": "13.1"}, {"groupId": "BG002", "value": "61.9", "spread": "13.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "45"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "208"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "74"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "91"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "169"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "126"}, {"groupId": "BG001", "value": "124"}, {"groupId": "BG002", "value": "250"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "184"}]}]}, {"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "69"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "A Composite Clinical Endpoint (CCE) That Classifies Subject's Clinical Status as Improved, Worsened, or Unchanged.", "description": "CCE composed of 3-level categorical variable with options that include worsened, unchanged or improved", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "24 Weeks", "groups": [{"id": "OG000", "title": "Allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nallopurinol: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}, {"id": "OG001", "title": "Sugar Pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nsugar pill: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Worsened", "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "58"}]}]}, {"title": "Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "43"}]}]}, {"title": "Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "24"}]}]}]}, {"type": "SECONDARY", "title": "Change in Quality of Life (KCCQ).", "description": "Kansas City Cardiomyopathy (KCCQ) overall summary score - The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.", "populationDescription": "Participants analyzed included those patients who had complete data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nallopurinol: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}, {"id": "OG001", "title": "Sugar Pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nsugar pill: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "112"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.45", "spread": "15.42"}, {"groupId": "OG001", "value": "3.38", "spread": "19.43"}]}]}]}, {"type": "SECONDARY", "title": "Change in Submaximal Exercise Capacity (6-MWT)", "description": "6-Minute Walk Test", "populationDescription": "Participants analyzed included those patients who had complete data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nallopurinol: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}, {"id": "OG001", "title": "Sugar Pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nsugar pill: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "104"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.5", "spread": "77.2"}, {"groupId": "OG001", "value": "9.5", "spread": "83.5"}]}]}]}, {"type": "SECONDARY", "title": "Change in Quality of Life (KCCQ)", "description": "Kansas City Cardiomyopathy (KCCQ) overall summary score - The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.", "populationDescription": "Participants analyzed included those patients who had complete data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline to 24 weeks", "groups": [{"id": "OG000", "title": "Allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nallopurinol: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}, {"id": "OG001", "title": "Sugar Pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nsugar pill: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.13", "spread": "18.89"}, {"groupId": "OG001", "value": "4.68", "spread": "21.02"}]}]}]}, {"type": "SECONDARY", "title": "Change in Submaximal Exercise Capacity (6-MWT)", "description": "6-Minute Walk Test", "populationDescription": "Participants analyzed included those patients who had complete data for this endpoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "Baseline to 24 weeks", "groups": [{"id": "OG000", "title": "Allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nallopurinol: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}, {"id": "OG001", "title": "Sugar Pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nsugar pill: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.1", "spread": "86.4"}, {"groupId": "OG001", "value": "20.7", "spread": "86.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "eventGroups": [{"id": "EG000", "title": "Allopurinol", "description": "Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nallopurinol: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.", "seriousNumAffected": 25, "seriousNumAtRisk": 128, "otherNumAffected": 88, "otherNumAtRisk": 128}, {"id": "EG001", "title": "Sugar Pill", "description": "Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.\n\nsugar pill: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.", "seriousNumAffected": 19, "seriousNumAtRisk": 125, "otherNumAffected": 64, "otherNumAtRisk": 125}], "seriousEvents": [{"term": "Upper Gastrointestinal Hemorhage", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Anticoagulation Drug Level above Therapeutic", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Hyperkalemia", "organSystem": "Metabolism and nutrition disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 125}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Diarhea", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Gastrointestinal perforation", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Device dislocation", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Atypical pneumonia", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Anticoagulation drug level below therapeutic", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Diabeties Mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}], "otherEvents": [{"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Fatigue", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 125}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 125}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 125}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 125}]}, {"term": "Hyperkalemia", "organSystem": "Metabolism and nutrition disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Hypokalemia", "organSystem": "Metabolism and nutrition disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 125}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Muscle Spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 125}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 125}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 125}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 125}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Kevin Anstrom", "organization": "Duke University", "email": "kevin.anstrom@dm.duke.edu", "phone": "919-668-8902"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M24343", "name": "Hyperuricemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000493", "term": "Allopurinol"}], "ancestors": [{"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000006074", "term": "Gout Suppressants"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000016166", "term": "Free Radical Scavengers"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M17277", "name": "Uric Acid", "relevance": "LOW"}, {"id": "M3834", "name": "Allopurinol", "asFound": "African", "relevance": "HIGH"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}]}}, "hasResults": true}